{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Animal models",
      "Clinical trials",
      "Covid-19",
      "SARS-CoV-2",
      "Vaccines"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34022375",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "01",
    "Day": "28"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "20"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.micinf.2021.104841",
      "S1286-4579(21)00063-0"
    ],
    "Journal": {
      "ISSN": "1769-714X",
      "JournalIssue": {
        "Volume": "23",
        "Issue": "8",
        "PubDate": {
          "Year": "2021",
          "Season": "Sep-Oct"
        }
      },
      "Title": "Microbes and infection",
      "ISOAbbreviation": "Microbes Infect"
    },
    "ArticleTitle": "Development of leading first-generation vaccines against SARS-CoV-2.",
    "Pagination": {
      "StartPage": "104841",
      "MedlinePgn": "104841"
    },
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 has infected more than 167 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need."
      ],
      "CopyrightInformation": "Published by Elsevier Masson SAS."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Washington, DC, USA. Electronic address: Pin-Yu.Perera@va.gov."
          }
        ],
        "LastName": "Perera",
        "ForeName": "Pin-Yu",
        "Initials": "PY"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA."
          }
        ],
        "LastName": "Perera",
        "ForeName": "Liyanage P",
        "Initials": "LP"
      }
    ],
    "GrantList": [
      {
        "GrantID": "UL1 TR001409",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "UL1 TR000101",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, U.S. Gov't, Non-P.H.S.",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Microbes Infect",
    "NlmUniqueID": "100883508",
    "ISSNLinking": "1286-4579"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "Declaration of competing interest No conflicts to disclose."
}